Ginsenoside Rb1 for Myocardial IschemiaReperfusion Injury: Preclinical Evidence and Possible Mechanisms

Abstract EN

Ginseng is an important herbal drug that has been used worldwide for many years.

Ginsenoside Rb1 (G-Rb1), the major pharmacological extract from ginseng, possesses a variety of biological activities in the cardiovascular systems.

Here, we conducted a preclinical systematic review to investigate the efficacy of G-Rb1 for animal models of myocardial ischemia/reperfusion injury and its possible mechanisms.

Ten studies involving 211 animals were identified by searching 6 databases from inception to May 2017.

The methodological quality was assessed by using the CAMARADES 10-item checklist.

All the data were analyzed using RevMan 5.3 software.

As a result, the score of study quality ranged from 3 to 7 points.

Meta-analyses showed that G-Rb1 can significantly decrease the myocardial infarct size and cardiac enzymes (including lactate dehydrogenase, creatine kinase, and creatine kinase-MB) when compared with control group (P<0.01).

Significant decrease in cardiac troponin T and improvement in the degree of ST-segment depression were reported in one study (P<0.05).

Additionally, the possible mechanisms of G-Rb1 for myocardial infarction are antioxidant, anti-inflammatory, antiapoptosis, promoting angiogenesis and improving the circulation.

Thus, G-Rb1 is a potential cardioprotective candidate for further clinical trials of myocardial infarction.